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PERSPECTIVES IN RENAL MEDICINE
Pain management in polycystic kidney disease
ZAHID H. BAJWA, SANJAY GUPTA, CAROL A. WARFIELD, and THEODORE I. STEINMAN
Department of Anesthesia and Neurology, Department of Anesthesia, and Renal Division, Department of Medicine,
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Pain management in polycystic kidney disease. Pain is a com- als at risk would be at least two renal cysts (unilateral
mon complaint in patients with autosomal-dominant polycystic or bilateral). More stringent criteria in those aged 30 to
kidney disease, and a systematic approach is needed to differen- 59 years to establish a diagnosis is the presence of attiate the etiology of the pain and define an approach to manage-
least two cysts in each kidney. For at-risk individuals 60ment. A thorough history is the best clue to the multifactorial
years and older, at least four cysts in each kidney shouldcauses of the pain, superimposed upon an understanding of the
complex innervation network that supplies the kidneys. The be required. Other reviews of ADPKD have established
appropriate use of diagnostic radiology (especially MRI) will less exact criteria to establish a diagnosis [3, 4]. Although
assist in differentiating the mechanical low back pain caused there are other etiologies of polycystic kidney disease,by cyst enlargement, cyst rupture and cyst infection. Also, the
including autosomal-recessive disease and acquired cys-increased incidence of uric acid nephrolithiasis as a factor in
tic kidney disease (generally associated with chronic fail-producing renal colic must be considered when evaluating acute
pain in the population at risk. MRI is not a good technique to ure) [5, 6], ADPKD is by far the most common and best
detect renal calculi, a frequent cause of pain in polycystic kid- studied of these cystic entities. Hence, ADPKD will be
ney disease. If stone disease is a possibility, then abdominal
used as the prototype form of polycystic kidney diseaseCT scan and/or ultrasound should be the method of radiologic
throughout this review.investigation. Pain management is generally not approached
in a systematic way in clinical practice because most physicians End-stage renal disease (ESRD) ultimately occurs in
lack training in the principles of pain management. The first approximately 50% of patients with ADPKD by 60 years
impulse to give narcotics for pain relief must be avoided. Since of age, and over the slow course of the disease there are
chronic pain cannot be “cured,” an approach must include
a constellation of symptoms and associated findings. Thetechniques that allow the patient to adapt to chronic pain so
spectrum of pain is the focus of this article. About 30%as to limit interference with their life style. A detailed stepwise
approach for acute and chronic pain strategies for the patient of ADPKD patients have accompanying polycystic liver
with autosomal dominant polycystic kidney disease is outlined. disease upon presentation. However, the presence of
liver cysts is age-dependent in ADPKD patients and may
eventually be noted in up to 75 to 80% of these patients.
Pain is a common complaint in patients with autosomal- Liver cysts are associated with various pain patterns (de-
dominant polycystic kidney disease (ADPKD), afflicting tails below). Radiographic imaging techniques such as
about 60% of patients with an established diagnosis [1]. computed tomography (CT), ultrasound, and magnetic
The sensitivity of ultrasound to confirm a diagnosis of resonance imaging (MRI) are sensitive enough to detect
ADPKD in individuals who have a 50% a priori risk of cysts at a relatively early age and can help define which
having the disease by genetic linkage was studied by cysts are the largest and most amenable to approach [7].
Ravine et al [2]. Currently used criteria of bilateral cysts Headache pain in the polycystic kidney disease popu-
with at least two in one kidney provides a sensitivity of lation generates anxiety about the potential for a cerebral
88.5% at age 15 to 29 years and 100% at 30 years of age aneurysm. Detection varies between 0 and 40% of this pa-
and above. Less stringent criteria in subjects aged 15 to tient group in multiple studies [8–10]. However, the real-
29 years to establish a diagnosis of ADPKD for individu- istic estimate is between 4 and 6% of the total ADPKD
patient group. When a family history of cerebral aneu-
rysms is noted, the incidence of aneurysms increases 18
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to 26% [11]. Headache pain patterns will not be discussedrenal calculi, stone disease, computed tomography, magnetic resonance
imaging, ADPKD. further in this review, but it should be noted that in a
survey of 184 patients with polycystic kidney diseaseReceived for publication July 13, 2000
conducted when we began to explore the issue of pain,and in revised form February 19, 2001
Accepted for publication April 9, 2001 the frequency of headaches is the same as in the general
population. Chronic and migraine headaches are not re- 2001 by the International Society of Nephrology
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lated to the presence of aneurysms. In 40 polycystic kid-
ney disease patients with severe recurring headaches,
none had a detectable cerebral aneurysm by magnetic
resonance angiography (MRA).
Hematuria related to cyst rupture, urinary tract infec-
tions (UTIs) and nephrolithiasis occur in many patients
with ADPKD and the associated pain patterns are dis-
cussed in detail in this review. Severe persistent abdomi-
nal and flank pain affects patients afflicted with ADPKD
[12, 13] and is a source of great frustration for those
individuals because pain management is not well handled
by many physicians. Segura et al outlined a detailed
medical and surgical approach to chronic pain in renal
cystic diseases [14], and this review is an update since
their book chapter.
SENSORY AND AUTONOMIC INNERVATION
TO THE KIDNEYS
To discuss the pain associated with ADPKD, it is im-
portant to appreciate the diverse nerve supply to the
kidneys. The kidneys and ureters are well supplied by
sympathetic, parasympathetic and sensory afferent fibers
(Fig. 1), and the renal sensory innervation is clearly asso-
ciated with the perception of pain in the affected individ-
uals. Schematic illustration of the autonomic and sensory
nerve pathways supplying the kidneys and ureters in
Figure 1 comes from the detailed work of Ansell, Gee,
and Bonica [15].
The sympathetic supply of the kidneys comes from
the aorticorenal and celiac ganglia as well as from the
cephalad portion of the lumbar sympathetic trunk. The
sympathetic nerves supplying the kidneys originate in
spinal cord segments T10 to L1, traveling via the white
rami communicates to the paravertebral ganglia. From
Fig. 1. Sympathetic, parasympathetic and sensory enervation supply-the 10th and 11th thoracic paravertebral ganglia, the
ing the kidney. The solid line ( ) represents the sympathetic compo-sympathetic nerves travel via the lesser splanchnic nerves nent. The dotted line (. . . . .) reflects the parasympathetic nerve supply.
to synapse at the ipsilateral aorticorenal and celiac gan- Afferent (sensory) fibers are represented by the dashed line (- - - -) and
travel with the autonomic nerves See text for details. (Reproduced withglia. From the 12th thoracic paravertebral ganglion, nerves
permission from Lippincott, Williams and Wilkins [14]).travel via the least splanchnic nerve to synapse either in
the aorticorenal ganglion or in the renal plexus. Also,
the first lumbar splanchnic nerve synapses in the renal
plexus. The post-ganglionic sympathetic nerves from the short post-ganglionic fibers. The parasympathetics sup-
aorticorenal and celiac plexi also join the renal plexus. ply the muscles in the renal pelvis and calyces, but not
These nerves thus distribute to and innervate the vascu- the parenchyma of the kidneys.
lar musculature and smooth muscles of the renal calyces Sensory innervation of the kidneys comes from the
and renal pelvis. They also extend along the afferent 10th through 12th thoracic spinal nerves, which pass
arterioles all the way to the juxtaglomerular apparatus. through the thoracic sympathetic ganglia, and travel via
The parasympathetic innervation of the kidneys origi- the splanchnic nerves to the renal plexus and then to
nates from the vagus nerve. Most of these parasympa- the kidneys. Afferent sensory fibers traveling with the
thetic nerves traverse through the celiac plexus to the vagus nerve may explain the nausea that sometimes ac-
renal plexus; some bypass the celiac plexus and pass companies pain. Perception of renal pain is mainly in
directly to the renal plexus. Via the renal plexus, the unmyelinated C-fibers, while the pelvis and calyces are
preganglionic parasympathetics travel to the smooth innervated by thinly myelinated (A-delta) fibers from the
kidney, coursing through the periarterial nerves [16, 17].muscles of the renal pelvis where they synapse with the
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Interestingly, it was found on the feline model that 95% biotics generally can improve delivery into the cyst [21].
Therefore, many antibiotics such as the penicillins, ceph-of the spinal cord dorsal horn neurons that were acti-
vated by renal sensory afferents also had receptive fields alosporins, and aminoglycosides that have traditionally
been first line therapy for severe UTIs may not be effec-on the skin in the appropriate dermatomes [18]. There
is also extensive cross connection with innervation to tive in ADPKD. Drugs with good cyst-penetrating abil-
ity, such as clindamycin, trimethoprim-sulfamethozazole,other visceral structures, suggesting that renal pain can
manifest either in a localized or referred pattern. For metronidazole, and fluoroquinolones may be more effec-
tive. However, it is possible that even these may not beexample, stimulation of the kidney at the renal pelvis
produces pain at the costovertebral angle ipsilaterally effective, necessitating surgical drainage of the infected
cysts. It is imperative that these UTIs be promptly treatedand also can frequently be referred to the ipsilateral
testicle or ovary. to prevent ongoing pain and other complications in these
noncommunicating infected cysts such as sepsis, perin-
ephric abscess, and subsequent renal failure [22, 23].
ACUTE PAIN IN ADPKD
Pain in patients with polycystic kidney disease can be Hemorrhage
both acute and chronic, often being difficult to manage Another common cause of acute flank pain in associa-
in patients with more severe symptoms. However, with tion with gross hematuria in ADPKD is the rupture of
the utilization of a variety of traditional and recently avail- cysts. Hemorrhage may be into a communicating urinary
able pain management techniques, pain can be managed tract [24]. However, it is not certain that gross hematuria
effectively in most of these patients. In addition, patients represents hemorrhage into cysts communicating with
can be taught “how to live with their pain” since perma- the urinary tract, since most cysts derived from proximal
nent cure of chronic pain is often not a realistic goal. and distal tubule segments grow as a result of aberrant
Behavioral modification approaches can help patients tubulogenesis, and become walled off and separate from
adapt to chronic pain so as to not interfere with their life- the tubules of origin by the time they become detectable
style. ADPKD patients may suffer complications such as by imaging studies [25]. Gross hematuria is present in
infected cysts, cyst rupture/hemorrhage, and nephrolithi- as many as 43% to greater than 50% of the patients with
asis that often cause crippling acute renal pain. Discussed polycystic kidney disease [26]. Hemorrhage into a cyst
below are the most common etiologies of acute pain. occurs without gross hematuria when there is no commu-
nication with the urinary tract. The frequency of hematu-
Infection ria from cyst rupture correlates directly with the size
Infected cysts can cause diffuse pain that may be uni- of the kidneys, the incidence of hematuria increasing
lateral or bilateral, and the pain pattern can be similar to dramatically when one or both of the kidneys is larger
pyelonephritis in patients with noncystic kidneys. UTIs than 15 cm [27]. Also, hypertensive ADPKD subjects are
in patients with ADPKD, however, can be much more more likely to have gross hematuria than normotensive
difficult to diagnose and manage than in patients with patients. Prognostic characteristics are noted with gross
non-cystic kidneys. UTIs occur in many patients with hematuria; the greater the number of episodes, the worse
ADPKD and, as expected, the incidence is much higher the prognosis. Increased episodes of gross hematuria
in women than in men. In one report, 68% of women are noted in association with a higher baseline serum
with ADPKD had UTIs as compared with only 19% creatinine and episodes of bleeding before age 30 carry
of men [19]. Both hematogenous spread and ascending a worse renal outcome [28].
infection are the presumed causes for cyst involvement. In general, the episodes of hematuria are usually self-
A sudden increase in flank pain associated with fever is limited, lasting two to seven days. These episodes tend
the most common presentation of cyst infection. The to resolve spontaneously with conservative management
pain pattern tends to stay in one general area without consisting of bedrest and hydration, but persistent bleed-
radiation, not being relieved by position change. Infected ing has been noted to occur for weeks. Pain related to
cysts may not be in communication with the draining cyst rupture tends to be localized and definable by finger
urinary tract in patients with ADPKD and hence the point. However, referred pain to another location in the
urinalysis may be relatively benign and the urine cultures abdomen or up to the shoulder (for example, with right
can be persistently negative [20]. kidney cyst rupture simulating biliary colic) can occur
Management of upper tract infections in ADPKD may with hemorrhage into a larger cyst, resulting in compres-
be difficult, since antibiotics may not be able to cross the sion of surrounding structures.
epithelial lining of the cysts and produce a high enough It is possible for significant bleeding into the renal
concentration in the cyst fluid. Highly ionized water- cysts to occur with subsequent formation of clots. This
soluble drugs may have a low ability to penetrate this in turn may lead to urinary tract obstruction and severe
renal colic. Prolonged bed rest, intravenous hydration,barrier, whereas the use of nonionized lipid soluble anti-
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heat and judicious narcotic administration are often nec- no difference in other normal value urinary parameters,
including urinary oxalate, between ADPKD stone for-essary in this circumstance.
It is also possible for cysts on the surface of the kidneys mers and non-stone formers.
Renal function of adult ADPKD patients with kidneyto rupture and subsequent hemorrhage can result in a
subcapsular hematoma. The patient may then experience stones is significantly worse than in patients without
stones. ADPKD stone formers have larger predominanta mild steady flank pain until the hematoma has been
reabsorbed. Although nonsteroidal anti-inflammatory cyst size compared to non-stone formers. Increased cyst
number also is associated with stone formation (abstract;drugs (NSAIDs) may be very helpful in the case of col-
icky pain, they must be used cautiously and should not Glass et al, J Urol 155:643A, 1996). Therefore, anatomic
deformity related to cyst number, size, and growth maybe the first line of treatment (see section on Systemic
Analgesics). Hematuria may rarely be so severe and/or contribute to the formation of kidney stones, possibly
through a mechanism of increased urinary stasis [34].persistent as to necessitate transfusion. In these cases,
either nephrectomy or renal arterial embolization may Because of the compressed and distorted renal calices,
treatment modalities such as ureteroscopy, extracorpo-be necessary to control the bleeding. Embolization, al-
though less invasive than nephrectomy, can in itself cause real shock wave lithotripsy (ESWL), and nephrolithot-
omy are more difficult in patients with ADPKD [35–38].severe continuous pain associated with abdominal dis-
tension. This pain is due to renal parenchymal ischemia Since these therapeutic and palliative procedures may
not be as efficacious, ADPKD patients may have to en-in an enlarged kidney following embolization, and can
be difficult to control with conservative management and dure prolonged and repeated episodes of renal colic while
undergoing medical management addressed towards thenon-opioid pharmacologic intervention. Even with high
doses of systemic opioids, the pain control can often be etiology of the stone formation. A rapidly progressive
distension produced by stone movement usually causesinadequate. However, a combination of epidural anes-
thesia and analgesia, using a mixture of local anesthetic a much more severe pain than a slowly increasing disten-
sion. Thus, it is critical that pain control be adequatelyand opioids during the procedure, and for several days
thereafter, may be an excellent way of controlling such addressed while a detailed evaluation is underway.
Renal prostaglandins may be a major contributing fac-severe pain (see section on Sequential Approach to Pain
Management) [29]. tor in the symptom complex known as renal colic. Acute
ureteral obstruction by a stone can increase renal pres-
Nephrolithiasis sure, leading to a release of inflammatory mediating re-
nal prostaglandins [39]. These prostaglandins, especiallyRenal colic caused by kidney stones, another compli-
cation of ADPKD, occurs in about 20% of patients with prostaglandin E2 (PGE2), cause vasodilation of the affer-
ent arterioles in the kidney and inhibition of antidiureticADPKD [30]. When considering the spectrum of both
symptomatic and asymptomatic stones, about a third of hormone (ADH), with a resultant diuresis and a further
increase in renal pressure. Thus, a vicious cycle may bethe ADPKD patients have nephrolithiasis. This much
higher incidence of nephrolithiasis than in the general established [40]. In the rabbit, prostaglandins also can
increase the contractile movement in the smooth musclepopulation is a cause of significant morbidity in ADPKD
patients because of flank pain, hematuria and urinary of the renal pelvis while promoting edema and inflam-
mation in the smooth muscle of the affected areas [41].tract infection. The prevalence of renal calcifications,
which represent stones within the collecting system, in- Prostaglandin synthesis inhibitors, such as NSAIDs,
would seem to be the obvious logical choice in combatingterstitial calcifications, or calcifications within cysts, was
found to be 50% by CT in a study by Levine and Grant- pain from kidney stones. NSAIDs’ administration leads
to an immediate reduction in smooth muscle movementham [31]. While patients with ADPKD develop a variety
of kidney stones (calcium oxalate, calcium phosphate, in the ureter as well as to a decrease in diuresis by counter-
acting the PGE2 effects on inhibiting ADH [42]. NSAIDscalcium carbonate, struvite), uric acid stones are more
common in polycystic kidney disease patients as com- will decrease inflammation and edema, allowing stone
passage down the ureter. Studies comparing the efficacypared to the incidence in the general population, ac-
counting for up to 50% of the calculi formed [32, 33]. of NSAIDs, especially indomethacin versus opioid anal-
gesic preparations, in relieving renal colic have shownMechanisms responsible for the increased association
between ADPKD and nephrolithiasis remain conjecture. that NSAIDs are as effective, if not more so, in providing
pain relief for this situation. Hetherington and Philip re-Patients with ADPKD may be predisposed to stone for-
mation either because of a metabolic defect, structural ported a 93% satisfactory pain relief from renal colic with
intramuscular diclofenac [43]. Another study showed thatabnormality secondary to cyst growth, renal tubular sta-
sis, or a combination of these factors. It is noted that a single dose of 10 mg of parenteral ketorolac was as ef-
ficacious as 100 mg of intramuscular meperidine in thisapproximately 50% of ADPKD patients have hypocitra-
turia (abstract; Fan et al, J Urol 155:643A, 1996). There is setting [44].
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Non-steroidal anti-inflammatory drugs must be used observation that the greatest degree of hypertrophy oc-
curs in patients who have the largest kidney cyst volume.judiciously, avoiding prolonged use in patients who have
renal compromise secondary to ADPKD. Short-term use Therefore, muscle enlargement could be the basis of the
“imbalance” and the major cause for chronic low backseems reasonable, limiting the NSAID administration to
no more than two to three days. Even healthy people pain in this population. This slow process contrasts to the
pain pattern related directly to cyst formation/compres-with intact renal function have reported acute flank pain
and renal dysfunction associated with use of NSAIDs [45]. sion. As in the general population, the problem of back
pain is complex and requires a thorough evaluation toIt is yet unproven that cyclooxygenase-2 (COX-2) in-
hibitors may be more renoprotective. Since it is stated ascertain the exact cause. If MRI demonstrates lumbo-
dorsal muscle hypertrophy, then the focus should be onthat COX-2 inhibitors will not interfere with renal PGE
synthesis, they supposedly will not inhibit the vasodila- treating mechanical back pain. For diffuse low back pain,
physical therapy techniques and trigger-point injectionstory and ADH effects of PGE2. However, COX-2 is con-
stitutively expressed in the kidney and is up-regulated using either local anesthetics alone or in combination with
steroids can be helpful. Also, a combination of physicalduring sodium restriction. Therefore, these agents to
some extent interfere with renal prostaglandin synthesis therapy and transcutaneous electrical nerve stimulation
(TENS) unit use can be an adjunctive maneuver [46].(see section on Systemic Analgesics for a detailed discus-
sion on COX-2 inhibitors). Since bilateral cyst enlargement can be asymmetric,
the pelvic shift in posture tends to produce low back painOpioids are still the cornerstone of analgesic therapy
for acute renal colic, even though they do not influence localized to one side more than the other. This chronic
alteration in posture appears to accelerate the develop-renal prostaglandins or renal pelvic pressure. An in-
crease in the tonicity of smooth muscle occurs with opi- ment of disc disease in the lumbosacral region. When
polycystic liver disease compounds the picture, the pos-oids and subsequent ureteral spasm during colic is not
desirable. Also, the possible buildup of active and poten- tural changes become more pronounced and subsequent
back pain can be a debilitating complication. Therefore,tially toxic metabolites of certain opioids, such as nor-
meperidine, need to be considered in patients with renal an MRI may demonstrate disc disease with or without
muscle hypertrophy, and this radiologic study becomesfailure who may receive Demerol for as short as three
to four days. Even after stopping this opioid, a near an essential tool in assessing back pain in this population.
For ADPKD patients with spinal stenosis or lumbo-coma-like state can persist for days.
sacral radiculopathy due to disc disease or degenerative
spine disease, epidural steroid injections are often help-
CHRONIC PAIN IN ADPKD
ful [47, 48]. These injections also can be performed for
Mechanical back pain in ADPKD thoracic or cervical radiculopathy that results from disc
disease or degenerative changes of the spine. Facet blocksChronic back pain is a common and frustrating prob-
lem in this population. Enlarging cysts can cause in- can have diagnostic and therapeutic value if facet arthri-
tis is the source of pain. Pain arising from the sacroiliaccreased abdominal girth, leading to increased lumbar lor-
dosis that accelerates degenerative changes in the spine. joint is frequently under-diagnosed and seems to be a
common source of pathology in patients with polycysticThis “imbalance” of the spine can be the source of a
variety of different pain syndromes. The mechanical form kidney disease. Injections using a combination of local
anesthetics and steroids as well as physical therapy tech-of back pain tends to get worse with passage of time. A
personal observation made during an APDKD Cohort niques can alleviate pain.
Study to determine the volume of kidney cysts via MRI
Chronic pain related to cyst formationdemonstrated hypertrophy of the lumbodorsal muscle
group. Ten patients with ADPKD had an average lumbo- Pain can occur due to compression of cysts on the
surrounding tissues, traction on the pedicle of the kidney,dorsal muscle thickness at the L4-S1 level of 38.7 mm.
In contrast, ten age- and gender-matched non-ADPKD and distension of the renal capsule. The pain severity
generally correlates with the size of the kidneys, butpatients, who had undergone an abdominal MRI for a
variety of reasons, had a 31.3 mm thickness of this muscle there are some marked exceptions. Some patients with
relatively small cysts, less than 3 cm, can have severegroup measured at the same level. The ADPKD patients
were known to have the disease at least ten years, and pain while others with very large cysts do not experience
much discomfort. The reason for this variation is notall, except for one, had a serum creatinine equal to or
less than 1.4 mg/dL at the time of study. A more detailed clear. Pain related directly to cyst formation tends to be
a steady nagging discomfort, with the standing positionstudy now will be conducted to see if this preliminary
observation of an average 7.4 mm difference on lumbo- and walking exacerbating the discomfort. Patients can
frequently localize the source of pain with one finger,dorsal muscle group hypertrophy is a reproducible find-
ing. There will be a need to document our preliminary anterior abdominal being more common than localized
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back pain. However, the pinpoint pain does not readily when the initial step(s) of intervention do not bring de-
sired results. Repeatedly, it must be emphasized that thecorrelate with the largest sized cysts noted on radiologi-
goal of treatment is to have the patient adapt to theircal imaging (ultrasound, CT scan, MRI).
pain, since cure of chronic pain is infrequent. ReductionWith massive cyst formation early satiety can occur
of interference with a desired lifestyle should be an ex-due to compression of the greater curvature of the stom-
pressed tenet of treatment. This generalized approachach and /or duodenal loop, (the two most common gas-
fits into the framework of psychobehavioral modificationtrointestinal abnormalities noted on CT scan with con-
and should be an integral part of any chronic pain treat-trast). Pain related to enlarging cysts does not correlate
ment program.with the level of renal function. Severe discomfort is
The various options for an effective combined and se-noted at all levels of kidney function; when pain is the
quential chronic pain management in ADPKD are notedpredominant complaint it begins early in the course of
in Figure 2. They can be summarized as follows: (1) phys-demonstrable cyst formation. A detailed history focusing
ical measures (ice massage, heating pads, whirlpool, Al-pain location, duration, associated symptoms and ma-
exander technique); (2) psychobehavioral modificationneuvers to produce relief will frequently delineate pain
techniques; (3) systemic analgesics; and (4) physical in-related directly to cyst formation versus mechanical back
terventions such as (in sequential order), (a) TENS, (b)pain due to a change in posture from enlarging cysts.
acupuncture, (c) autonomic plexus blockade, (d) neuro-Polycystic liver disease in the patient with ADPKD
modulation by spinal cord stimulation, (e) neuraxial opi-can cause the most disabling pain pattern, often more
oids and local anesthetics, ( f) surgical decompressionsevere than that related to kidney cysts. Multiparous
of kidney and liver cysts, and (g) hepatectomy (partial)females appear to be the most affected group. Cysts can
and/or nephrectomy.become so massive as to occupy most of the abdominal
The severity of pain varies from patient to patient andcavity and produce intractable pain/discomfort that is
a combination of the above modalities may be mostresistant to every modality of therapy. Pain/discomfort
useful. Management of pain should initially be conserva-tends to be most severe when the patient is erect. Early
tive, employing non-narcotic analgesics and other non-satiety is noted frequently for the same reasons as above
invasive therapies. A sequential approach to pain man-due to polycystic kidneys, but this complaint occurs more
agement is advised as in Figure 2 and detailed below.frequently with liver cysts than with renal cysts. Manage-
ment approaches to pain are discussed below in detail,
outlining a stepwise treatment plan. NON-PHARMACOLOGIC THERAPY/
PHYSICAL MEASURES
Sequential approach to pain management
An initial attempt to control mild-to-moderate pain
All the approaches discussed below refer to general should be with simple adjuvants such as heating pads or
principles for pain control and are not specific for ice massage, even before trying non-narcotic analgesics.
ADPKD or chronic renal failure. However, our team Ice massage and heating may help decrease acute inter-
has used these modalities to address pain problems in mittent spasms, especially if muscle spasm is related to
our ADPKD population. Several of the principles result the pain. If the pain is due to enlarged cysts tugging on
from animal experimentation and other principles are de- the renal pedicles, supporting garments or corsets may
rived from clinical investigation in patients with chronic benefit the patient.
pain of various etiologies. The Alexander technique (AT) is a non-exercise ap-
A concept that must be employed in patients suffering proach to the improvement of body mechanics that in-
from chronic pain is not to set expectations too high. If volves a slow, long-term learning process [49–51]. Physi-
the patient is led to believe that permanent cure of cal manipulation while clothed is followed by learning
chronic pain will result from the planned intervention, how to hold and move your body in a correct anatomical
then disappointment and frustration will frequently oc- position. After many sessions with a certified AT teacher,
cur. A dissatisfied patient will lead to a scenario of doctor body positioning becomes “natural” and many musculo-
shopping and an expectant long list of both non-narcotic skeletal complaints are eliminated or markedly reduced
and narcotic analgesics constantly being consumed by [52]. In addition, the AT has been shown to reduce de-
the disgruntled patient. The most important first step by pression and improve the management of disability in a
the physician is to non-judgmentally listen to the patient, cohort of patients with Parkinson’s disease [53]. There
then validate the significance of their pain suffering. have been no controlled studies performed in ADPKD
Since pain cannot be directly measured, an expression patients with refractory pain, but personal observation
of understanding of their situation is a major part of the in isolated cases indicates that AT should be part of the
therapeutic intervention. Verification of their symptom therapeutic armamentarium for pain relief. Whirlpool
complex makes it easier for the patient to proceed with a treatments can be employed in conjunction with massage
therapy to enhance results with the AT.planned sequential approach to pain management, even
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Fig. 2. Pain management in polycystic kidney disease patients should follow a sequential approach, starting with measures that are noninvasive, sim-
ple and have relatively few side effects, and then slowly progress towards more complex and invasive measures. The first step is to set expectations
that pain may not be “cured,” but there will be adaptations that will allow the patient to adjust to the chronic pain. Combining different modalities
may be needed for refractory pain.
SYSTEMIC ANALGESICS mended by the National Kidney Foundation as the first
analgesic of choice for patients with preexisting renalAcetaminophen
disease and can be started at a dose of 500 to 650 mg
We recommend a step-ladder approach for the phar- orally every six hours as required for pain relief [54].
macologic therapy of pain, starting with the least poten- The dose can be increased to 1000 mg every four to
tially toxic agents and using higher sequential doses than six hours. There is a need to be aware that a clinically
usual before adding other drugs. Our suggestion would be important adverse event occurring with chronic acet-
to start with acetaminophen. It is effective in the treat- aminophen use can be prolongation of the half-life of
ment of mild to moderate pain and is devoid of any sig- warfarin [55]. While therapeutic doses of acetaminophen
nificant gastrointestinal side effects such as those associ- rarely are associated with hepatic toxicity, caution must
ated with aspirin and other NSAIDs. This low incidence be taken not to exceed 4000 mg per day since acetamino-
of gastrointestinal side effects makes acetaminophen phen has been associated with hepatotoxicity at high
doses in patients with existing liver disease. This drugparticularly useful in elderly. Acetaminophen is recom-
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should be avoided in patients with chronic alcohol abuse elderly patients receiving a low salt diet, the effects of
COX-2 inhibition on decreasing glomerular filtrationsince hepatic toxicity has been reported in this scenario
[56–58]. If a patient consumes three or more alcohol- rate (GFR) are similar to those observed with non-selec-
tive NSAIDs [68]. Therefore, this newest class of analge-containing drinks per day, clinicians should attempt to re-
duce this consumption before recommending chronic use sics must be used with caution in patients with mild to
moderate renal insufficiency and avoided in face of se-of any analgesic, including acetaminophen. With regards
to ADPKD, there is no evidence in the literature that vere impairment of kidney function (GFR 25 cc/min).
Potential drug interactions between COX-2 inhibitorsacetaminophen has kidney or liver toxicity (even in pa-
tients with extensive polycystic liver disease) that is dif- and angiotensin-converting enzyme inhibitors (ACEI),
warfarin and methotrexate exist [69]. COX-2 inhibitorsferent from other disorders causing chronic renal failure.
may reduce the antihypertensive effect of ACEI, increase
NSAIDs the effects of warfarin and increase methotrexate levels.
It has been postulated that COX-2 inhibitors may bindNon-steroidal anti-inflammatories (NSAIDs) are used
frequently by clinicians as first-line agents to control tumor necrosis factor (TNF), a protein associated with
joint pain and inflammation [70]. Since TNF is part of thepain, but therapy should be limited to several days in
patients with renal insufficiency because of the noted internal response to infections, the theoretical possibility is
raised that polycystic kidney disease patients with serioustoxicity profile. Antiplatelet action of NSAIDs may be
detrimental in the setting of hematuria. Also, renal func- infections or sepsis could possibly experience severe com-
plications if maintained on these agents. However, theretion may already be impaired despite a serum creatinine
in the “normal” range and careful monitoring of kidney is no clinical evidence to date to support such a relation-
ship between COX-2 inhibitors and infection. If COX-2function is necessary when NSAIDs are used even for
brief periods. Agents currently available inhibit both inhibitors are used, the dosage ranges between 100 to
200 mg bid for Celecoxib (12.5 to 50 mg qd b.i.d. forcyclooxygenase type I (COX-1) and II (COX-2). Cyclo-
oxygenase is required for the synthesis of prostaglandins Rofecoxib). As with NSAIDs, short-term use is recom-
mended until a complete clinical profile on this classand thromboxanes, and inhibition leads to blockage of
PG formation in inflamed tissues (via COX-2), as well of compounds is established. Considering the potential
toxicity, a better choice for pain control, after acetamino-as blocking prostaglandins in tissues like the stomach
and kidney (via COX-1). COX-1 is expressed constitu- phen, may be the non-acetylated salicylates, such as sal-
salate. Only after failure of relief with acetaminophentively in most tissues and is thought to play a major role
in protecting the gastric mucous [59]. Therefore, inhibi- and then salsalate should NSAIDs and COX-2 inhibitors
be tried for a short term.tion of COX-1 by NSAIDs, and the resultant blockage
of PG formation, is associated with renal toxicity and
gastric ulceration [60, 61] Catastrophic gastrointestinal
ADJUNCTIVE NON-NARCOTIC AGENTS
events in elderly patients taking NSAIDs occur in a dose-
Tramadoldependent manner [62]. Risk factors for reversible renal
failure in patients with intrinsic renal disease who are Tramadol (Ultram) is a centrally acting non-NSAID
analgesic with a dual mechanism of action, indicated fortreated with NSAIDs include age 65 or older, hyperten-
sion, congestive heart failure, and concomitant use of moderate to moderately severe pain. It is a mu opioid re-
ceptor agonist (binding affinity 6000 times less than mor-diuretics and/or angiotensin-converting enzyme inhibi-
tors [63, 64]. Given the above side effects, NSAIDs are phine) that also inhibits norepinephrine and serotonin
re-uptake by the nerve cells. The side effects include nau-not suitable for long-term use.
sea, somnolence, constipation, and vomiting. Abuse po-
COX-2 inhibitors tential in several European trials is claimed to be lower
than with other narcotics. Tramadol does not inhibit pros-The recently developed COX-2 inhibitors have a high
degree of selectivity for the inducible form of cyxlooxy- taglandin production and so it lacks any gastrointestinal
and renal prostaglandin-inhibiting side effects. In cases ofgenase (COX-2) over the constitutive form (COX-1) and
are claimed to be associated with less gastric and renal moderate to severe pain, 50 to 100 mg of Tramadol may
be given every four to six hours. Patients on this analgesicside effects [65–67]. While these drugs are comparable
to NSAIDs for reducing pain, they do not interfere with while also taking Serotonin selective re-uptake inhibitor
(SSRI) antidepressants can develop a serotonin syndrome,platelet aggregation. Hence, fewer endoscopically de-
tected gastric and duodenal ulcers have been reported since Tramadol can also inhibit the re-uptake of seroto-
nin and norepinephrine [71]. This reaction, characterizedwhen compared to traditional NSAIDs. However, tar-
geted disruption of the COX-2 allele in mice has resulted by nausea, diaphoresis, muscle weakness, tremor and con-
fusion, can occur within a few days of taking both medica-in severe renal problems, supporting the clinical observa-
tion that COX-2 inhibitors can cause renal toxicity. In tions. Tramadol can be tried alone for analgesia, but it fre-
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quently can be effective as an adjunctive agent to another incidence of side effects because of lowered doses of
non-narcotic or narcotic agent. each agent. Acetominophen, salsalate, NSAIDs, COX-2
inhibitors, tramadol, or clonidine can be combined with
Clonidine opioids as long as there is an awareness of potential
Anesthesiologists have long used clonidine as a sole major side effects. Systematic pharmacologic interven-
or adjunctive agent for pain control. Analgesia is pro- tion needs to start with one drug and then follow a
duced by the action of clonidine on stimulating the sequence of stepwise additions as needed for chronic
2-adrenoceptors. Stimulation of the 2-adrenoceptors pain management in ADPKD patients.
reduces sympathetic outflow from the central nervous
system, a factor in pain control. Pain control is achieved
PHYSICAL INTERVENTIONSfrom systemic, epidural or intrathecal administration of
Transcutaneous electrical nerve stimulationclonidine. However, clonidine is more potent after neu-
raxial administration in contrast to systemic administra- Transcutaneous electrical nerve stimulation (TENS)
tion, indicating a spinal site of action [72]. With epidural unit application can be a useful adjunct [46, 74, 75],
clonidine administration there is a strong correlation be- especially if used as part of a stepwise sequence for pain
tween clonidine concentration in the cerebrospinal fluid control. In the cat, almost 95% of the dorsal horn cells
and analgesia [73]. For the ADPKD patient, clonidine is with renal input may get concomitant somatic receptive
recommended as an adjunctive agent, especially adding it field input. Nam et al showed that TENS electrodes
to local anesthetics for epidural, spinal or peripheral placed on the somatic receptive fields of these neurons
blockade since it prolongs and intensifies anesthesia. on the skin reduced their responsiveness to nociceptive
When epidural clonidine is used with opiates, the combi- stimuli [18]. TENS decreased the dorsal horn cell respon-
nation offers the advantage of reduced dose of each siveness to C-fiber direct electrical stimulation to about
component (with correspondingly fewer side effects). 39% of control. Also, the dorsal horn cell responsiveness
Clonidine, both in oral and transdermal patch forms, can to ureteral occlusion was decreased to 38% of control.
be a useful adjuvant for control of moderate to severe Finally, with renal artery occlusion, the dorsal horn cells
pain, especially if patients are requiring a large amount were only 46% as responsive with TENS use as com-
of opioid medications. pared to controls. These analgesic effects lasted from 10
Clonidine produces dose-dependent side effects of hy- to 15 minutes after the TENS unit was turned off. We
potension, bradycardia and sedation, and patients need
have found that intermittent use of a TENS unit can
to be warned about the consequences of such. In addi-
often help control chronic pain, especially in patients withtion, the concomitant use of tricyclic anti-depressants
chronic dull aching pain. A trial can be given for two(sometimes also used for adjunctive pain relief) may
weeks, and if found effective it can be used long termaccentuate the side-effect profile, but the hypotensive
with virtually no side effects.effects of clonidine may be reduced by combination use.
AcupunctureOpioids
Another useful adjunct can be acupuncture treatment.Opioids remain the mainstay of pain management for
Acupuncture and electrical stimulation of acupuncturemoderate to severe pain, especially if the pain is not
points are minimally invasive and avoid the side effectscontrolled by above non-opioid agents. The main con-
of analgesics. Pain relief with acupuncture occurs viacerns about the use of opioids are their side effects:
activation of the gate-control system in which large nervenausea, vomiting, constipation, sedation and the poten-
fibers are stimulated and suppress small fibers that trans-tial for abuse. Also, if there is associated renal dysfunc-
mit signals in the dorsal horn of the spinal cord [76, 77] ortion, dose adjustment to less frequent intervals is neces-
through release of neurochemicals in the central nervoussary since excretion of these drugs may be prolonged.
system [78–80]. Lein et al showed that electrical stimula-For the purpose of chronic non-malignant pain control,
tion at various auricular, somatic, and combination groupopioids are usually administered orally or transdermally.
acupuncture points produced a significant elevation inBoth short acting and long acting preparations (12 to 24
pain threshold [46]. Yao reported that in the rabbithours) are available for oral use. Fentanyl patches are
model, electroacupunture to the hind leg produced par-available for transdermal use and can be very effective.
tial inhibition of the splanchnic nerve activity while in-Each patch provides analgesia for three days and the
creasing the inhibition of renal nerve activity caused bydosage starts at 25 g/h.
stimulation of the brain osmoreceptors with hypertonicThe most effective analgesia may be obtained by using
saline [75]. These examples and others show that furthera combination of opioid and other drugs. The delivery
investigation into acupuncture may be warranted as partof different classes of analgesics results in effective pain
relief by synergistic or additive effects with a reduced of chronic pain management in patients with ADPKD.
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Autonomic plexus blockade When needed, we suggest putting an epidural catheter
in on a trial basis. If found effective, a permanent epi-As discussed before, the autonomic nervous supply to
dural catheter can be implanted. The advantage of ankidney, both sympathetic and parasympathetic, relay via
epidural catheter is that local anesthetic agents have athe celiac plexus. Celiac plexus block is commonly used
higher margin of safety, while the disadvantage is thefor relief of cancer pain from various abdominal viscera
requirement of a larger volume of infusion necessitating[81]. An increasing number of pain specialists are now
an external pump with frequent refilling of medicationusing celiac plexus blocks for chronic nonmalignant pain
[91]. With an intrathecal catheter a much lower volume[82–84] and it could prove to be of significant benefit in
is required and therefore, an internal pump can be placedreducing pain in ADPKD patients. These blocks are usu-
(which requires refilling only about once a month).ally first done with local anesthetic agents, with or with-
out steroids, under fluoroscopic guidance. If relief is ob-
tained using local anesthetics, longer lasting results may SURGICAL MANAGEMENT
be obtained with the use of neurolytic blocks using alco-
If the above conservative measures fail to produce
hol or phenol [85]. Patients with moderate to severe pain
pain relief, surgical intervention may be necessary. An
would be good candidates for a celiac plexus block trial.
early employed technique was percutaneous aspiration
Neurolytic blocks may last anywhere from six months
of the cysts under ultrasound guidance [92]. Simple cyst
to a year.
aspiration can relieve pain temporarily, supporting the
hypothesis that cyst distention can be a cause of pain
[93]. Aspiration alone is inefficient because cysts willMAJOR INVASIVE PROCEDURES
re-accumulate fluid due to an active chloride transportSpinal cord stimulation
process. Percutaneous aspiration may be difficult second-
Neuromodulation of the spinal column by implanting
ary to the presence of multiple cysts; never knowing
electrodes in the epidural space is another method being
which cyst(s) is the major culprit for pain. Also, viscous
increasingly employed for chronic pain control. This is
cyst fluid may be difficult to aspirate. Rovsing, in 1911,
an invasive procedure and requires a long-term implan-
originally performed surgical de-roofing and drainage oftation of a device. The principle of action is probably
the cysts, and reported sustained reduction in renal sizesimilar to TENS, but has the additional benefit of more
[94]. However, this procedure was subsequently aban-central intense effects and is also devoid of the cutaneous
doned in the 1960s due to reports that the procedurediscomfort associated with a TENS unit. Before a perma-
itself accelerated renal damage [95].nent stimulator is implanted, a trial stimulator electrode
However, in the early 1980s He et al [96] and Zheng,is used for a few days to assess the beneficial effects. In
Zhao and Wu [97] reported two separate series of casesa selected group of patients, spinal cord stimulation (SCS)
where cyst decompression surgery resulted in excellentcan be an excellent choice for pain control. Since it is
improvement in renal function as well as effective, lastingan implanted device, it is important that the patient make
pain relief. This procedure was repeated by Elzinga eta well-informed decision about the implantation. For mod-
al, who reported that up to 80% of patients were painerate to severe pain it can be a very useful non-pharmaco-
free at 12 months postoperatively and 62% at 24 monthslogic way of providing partial to complete relief and can
after surgery [98]. Laparoscopic marsupialization ofbe used as an effective adjuvant [86, 87]. Research studies
symptomatic polycystic kidney disease was reported byalso suggest that SCS increases the local visceral blood
Brown et al in 1996 [99], a thorough extension of someflow and may help reduce pain related to ischemia.
earlier attempts at laparoscopic unroofing of both simple
Neuraxial opioids and local anesthetics renal cysts and painful polycystic kidneys [100–104]. At
12 to 28 months after laparoscopic marsupialization,If the pain is moderate to severe, opioids can be given
Brown and colleagues found that 50% of the polycysticvia the epidural or intrathecal route [88, 89]. The amount
patients were pain free. In contrast, 62% of patient withof opioids given by this route is significantly less (espe-
simple cysts were pain free. Subsequent studies demon-cially when given in conjunction with local anesthetics),
strated that laparoscopic surgery (decortication and mar-and thus the systemic side effects of opioids are reduced.
supialization) may be effective in relieving pain in pa-This route of administration with low opioid doses has
tients with ADPKD [105, 106].minimal motor, sensory or sympathetic effects, with a
In our own hands, laparoscopic cyst decortication (un-subsequent lower side-effect liability than systemic ther-
roofing and collapse of cysts) in selected cases has beenapy [90]. There can be dose-dependent motor blockade,
an effective modality to relieve pain. This laparoscopicurinary retention and skin numbness from the anesthetic
procedure is restricted to patients who have severe painadded to the opioid. Since it is an invasive procedure re-
attributed to cysts5 cm in diameter. Usually the proce-quiring a long-term catheter, other non-invasive or one-
time invasive procedures should be tried first. dure is done unilaterally in a single sitting and the aver-
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age number of cysts unroofed are between 30 and 70. cyst volume, increased with estrogen therapy as compared
to a control group of ADPKD women not taking estro-Pain relief has been permanent in the majority of patients
when followed for at least three years after the proce- gens. Abdominal symptoms became more pronounced in
the ADPKD patients on estrogen therapy, presumablydure. Renal function has not been improved nor has
there been an accelerated decline in function as a result because of the extensive hepatic cystic disease. Non-
pharmacologic and non-opioid pharmacology interven-of this procedure. Earlier reports of improved kidney
function [96, 97, 107] have not been supported by our tions tend to be ineffectual for pain/discomfort relief
related to massive liver cysts. There appears to be apersonal observation or subsequent studies after laparos-
copic or open intervention. Blood pressure transiently correlation between hepatic cyst size and number and the
occurrence of refractory discomfort related to abdominaldecreased for approximately two to four weeks after the
distention. When pain/discomfort becomes intolerablelaparoscopic surgery, but by one month post-procedure
or evidence of malnutrition appears due to early satietythe blood pressure was back to baseline (which was ele-
from cyst compression on the stomach, surgical ap-vated in most patients). Finally, in patients approaching
proaches can be employed. Dyspnea is also noted asESRD, nephrectomy may be the only option for pain
massive liver cysts can press on the diaphragm and thiscontrol, especially when renal function in the effected
problem may tip the balance toward surgery.organ is minimal on radionuclide scanning. Nephrectomy
Controversy exists with regards to the best manage-also may be done in preparation for eventual transplant
ment approach in patients with highly symptomatic poly-surgery, especially if the kidney has infected cysts or
cystic liver disease and depends on the particular charac-the massively enlarged kidneys represent a mechanical
teristics of each patient. Two approaches have receivedobstruction to allograft placement.
the most attention: fenestration techniques versus com-
bined liver resection-fenestration [109–111]. Both lapar-
RENAL DENERVATION oscopy and laparotomy have been used for the extensive
With the knowledge that visceral organ denervation fenestration technique. Because improvement in pain/
is a routine consequence of kidney transplantation and discomfort perception appears to correlate with a reduc-
leads to an insensate kidney with no alteration in renal tion in computed tomography determination of hepatic
function, a new approach has been developed by Valente cyst volume, the combined resection-fenestration maneu-
et al (personal communication) for a laparoscopic trans- ver offers the best chance to achieve the goal of pain
peritoneal approach for unilateral or bilateral renal de- reduction/relief [111]. Pain/discomfort relief occurs in al-
nervation without the need for autotransplantation. The most all patients immediately post-operative. However,
technique involves exposing the renal pedicle via the morbidity can occur in up to 50% of patients, mainly
from biliary complications. Other problems in the abovelaparoscope and isolating the peri-arterial nerve fibers.
reports noted to occur (less frequently) include cholecys-Circumferential dissection, using an ultrasonic shear re-
titis, small bowel obstruction, hemorrhage, pneumonia,section technique, divides the nerve fibers of the renal
thrombosis (Budd-Chiari syndrome), transient pleuraland intermesenteric plexi. Their preliminary report (in
effusion, and transient ascites. A warning note is offeredpress) notes excellent results in the first ADPKD patient
with regards to posterior liver cysts, since an acute Budd-with refractory pain. Clinical application of renal nerve
Chiari syndrome with subsequent death developed as ainterruption awaits further study, especially comparing
result of liver collapse after extensive fenestration ofthis procedure to laparoscopic cyst reduction approaches
posterior cysts [112].discussed above.
During a follow-up time extending out to 71 months
in the above noted studies, overall pain/discomfort relief
PAIN RELATED TO POLYCYSTIC is to be expected in the short run. In the largest series
LIVER DISEASE published to date [111], selected patients with severe
Pain, frequently expressed as chronic abdominal dis- symptomatic polycystic liver disease and favorable anat-
comfort, related to liver cysts can be problematic and omy did benefit from liver resection and fenestration
occurs across the spectrum of renal function (from nor- with acceptable morbidity and mortality. The extent of
mal to end-stage renal disease and persisting post-kidney hepatic resection and fenestration is important for long-
transplant). While impairment of kidney function is a term effectiveness of this procedure without a major
common consequence of ADPKD, liver function invari- increase in liver volume. However, recurrent symptoms
ably remains normal despite massive polycystic liver dis- did occur in a large percent of patients in the other noted
ease. A recent study concluded that post-menopausal studies [109, 110, 112], but generally milder than before
estrogen therapy selectively stimulated hepatic cyst en- surgery. An increase in liver volume has been observed
largement in women with ADPKD who also had polycys- in up to 40% of patients [110], and sequential computed
tomography pre- and postoperative surgery suggests thattic liver disease [108]. Hepatic cyst volume, but not renal
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